Key clinical point: Different gene expression in synovial tissue, compared with skin, may explain differing treatment responses for skin and joints in psoriatic arthritis treated with anti-TNF agents and the anti–IL-23/IL-12 inhibitor ustekinumab.
Major finding: Some patients with psoriatic arthritis have lower levels of gene expression for key drug targets in their synovial tissues.
Study details: Observational, open-label study in 27 patients with active psoriatic arthritis.
Disclosures: The study was supported by the Queen Mary University of London and the Fondazione Ceschina, and in part by grants from Versus Arthritis. No conflicts of interest were declared.
Nerviani A et al. Ann Rheum Dis. 2020. Nov 26. doi: 10.1136/annrheumdis-2020-218186.